Standard BioTools Inc [NASDAQ: LAB] stock went on an upward path that rose over 20719472% on Monday, amounting to a one-week price increase of more than 17.14%.
Over the last 12 months, LAB stock dropped by -29.71%. The one-year Standard BioTools Inc stock forecast points to a potential downside of -54201580.67. The average equity rating for LAB stock is currently 1.67, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $467.18 million, with 379.09 million shares outstanding and 365.93 million shares in the current float. Compared to the average trading volume of 1.29M shares, LAB stock reached a trading volume of 20719472 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Standard BioTools Inc [LAB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LAB shares is $2.38 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LAB stock is a recommendation set at 1.67. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
KeyBanc Capital Markets have made an estimate for Standard BioTools Inc shares, keeping their opinion on the stock as Sector Weight, with their previous recommendation back on February 27, 2025. While these analysts kept the previous recommendation, TD Cowen raised their target price to Buy. The new note on the price target was released on April 16, 2024, representing the official price target for Standard BioTools Inc stock. Previously, the target price had yet another raise to $3.25, while Jefferies analysts kept a Buy rating on LAB stock.
The Price to Book ratio for the last quarter was 1.03, with the Price to Cash per share for the same quarter was set at 0.68.
LAB Stock Performance Analysis:
Standard BioTools Inc [LAB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 17.14. With this latest performance, LAB shares gained by 18.27% in over the last four-week period, additionally sinking by -44.34% over the last 6 months – not to mention a drop of -29.71% in the past year of trading.
Insight into Standard BioTools Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Standard BioTools Inc [LAB] shares currently have an operating margin of -74.44% and a Gross Margin at 45.96%. Standard BioTools Inc’s Net Margin is presently recorded at -78.24%.
Return on Equity for this stock declined to -19.56%, with Return on Assets sitting at -19.56%.
LAB Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LAB. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Standard BioTools Inc go to 66.44%.
Standard BioTools Inc [LAB] Institutonal Ownership Details
There are presently around $73.07%, or 74.10%% of LAB stock, in the hands of institutional investors. The top three institutional holders of LAB stocks are: CASDIN CAPITAL, LLC with ownership of 63.96 million shares, which is approximately 17.1782%. VIKING GLOBAL INVESTORS LP, holding 58.65 million shares of the stock with an approximate value of $$103.81 million in LAB stocks shares; and VIKING GLOBAL INVESTORS LP, currently with $$38.5 million in LAB stock with ownership which is approximately 5.8424%.
